Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming

Abstract Photodynamic therapy (PDT) with redaporfin stimulates colon carcinoma (CT26), breast (4T1) and melanoma (B16F10) cells to display high levels of CD80 molecules on their surfaces. CD80 overexpression amplifies immunogenicity because it increases same cell (cis) CD80:PD-L1 interactions, which...

Full description

Bibliographic Details
Main Authors: Catarina S. Lobo, Maria Inês P. Mendes, Diogo A. Pereira, Lígia C. Gomes-da-Silva, Luis G. Arnaut
Format: Article
Language:English
Published: Nature Portfolio 2023-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-38862-8
_version_ 1797774218692132864
author Catarina S. Lobo
Maria Inês P. Mendes
Diogo A. Pereira
Lígia C. Gomes-da-Silva
Luis G. Arnaut
author_facet Catarina S. Lobo
Maria Inês P. Mendes
Diogo A. Pereira
Lígia C. Gomes-da-Silva
Luis G. Arnaut
author_sort Catarina S. Lobo
collection DOAJ
description Abstract Photodynamic therapy (PDT) with redaporfin stimulates colon carcinoma (CT26), breast (4T1) and melanoma (B16F10) cells to display high levels of CD80 molecules on their surfaces. CD80 overexpression amplifies immunogenicity because it increases same cell (cis) CD80:PD-L1 interactions, which (i) disrupt binding of T-cells PD-1 inhibitory receptors with their ligands (PD-L1) in tumour cells, and (ii) inhibit CTLA-4 inhibitory receptors binding to CD80 in tumour cells. In some cancer cells, redaporfin-PDT also increases CTLA-4 and PD-L1 expressions and virtuous combinations between PDT and immune-checkpoint blockers (ICB) depend on CD80/PD-L1 or CD80/CTLA-4 tumour overexpression ratios post-PDT. This was confirmed using anti-CTLA-4 + PDT combinations to increase survival of mice bearing CT26 tumours, and to regress lung metastases observed with bioluminescence in mice with orthotopic 4T1 tumours. However, the primary 4T1 responded poorly to treatments. Photoacoustic imaging revealed low infiltration of redaporfin in the tumour. Priming the primary tumour with high-intensity (~ 60 bar) photoacoustic waves generated with nanosecond-pulsed lasers and light-to-pressure transducers improved the response of 4T1 tumours to PDT. Penetration-resistant tumours require a combination of approaches to respond to treatments: tumour priming to facilitate drug infiltration, PDT for a strong local effect and a change in immunogenicity, and immunotherapy for a systemic effect.
first_indexed 2024-03-12T22:17:50Z
format Article
id doaj.art-635aa666182f4a30a63368b89c5bd10f
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-03-12T22:17:50Z
publishDate 2023-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-635aa666182f4a30a63368b89c5bd10f2023-07-23T11:12:27ZengNature PortfolioScientific Reports2045-23222023-07-0113111410.1038/s41598-023-38862-8Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical primingCatarina S. Lobo0Maria Inês P. Mendes1Diogo A. Pereira2Lígia C. Gomes-da-Silva3Luis G. Arnaut4CQC, Chemistry Department, University of CoimbraCQC, Chemistry Department, University of CoimbraCQC, Chemistry Department, University of CoimbraCQC, Chemistry Department, University of CoimbraCQC, Chemistry Department, University of CoimbraAbstract Photodynamic therapy (PDT) with redaporfin stimulates colon carcinoma (CT26), breast (4T1) and melanoma (B16F10) cells to display high levels of CD80 molecules on their surfaces. CD80 overexpression amplifies immunogenicity because it increases same cell (cis) CD80:PD-L1 interactions, which (i) disrupt binding of T-cells PD-1 inhibitory receptors with their ligands (PD-L1) in tumour cells, and (ii) inhibit CTLA-4 inhibitory receptors binding to CD80 in tumour cells. In some cancer cells, redaporfin-PDT also increases CTLA-4 and PD-L1 expressions and virtuous combinations between PDT and immune-checkpoint blockers (ICB) depend on CD80/PD-L1 or CD80/CTLA-4 tumour overexpression ratios post-PDT. This was confirmed using anti-CTLA-4 + PDT combinations to increase survival of mice bearing CT26 tumours, and to regress lung metastases observed with bioluminescence in mice with orthotopic 4T1 tumours. However, the primary 4T1 responded poorly to treatments. Photoacoustic imaging revealed low infiltration of redaporfin in the tumour. Priming the primary tumour with high-intensity (~ 60 bar) photoacoustic waves generated with nanosecond-pulsed lasers and light-to-pressure transducers improved the response of 4T1 tumours to PDT. Penetration-resistant tumours require a combination of approaches to respond to treatments: tumour priming to facilitate drug infiltration, PDT for a strong local effect and a change in immunogenicity, and immunotherapy for a systemic effect.https://doi.org/10.1038/s41598-023-38862-8
spellingShingle Catarina S. Lobo
Maria Inês P. Mendes
Diogo A. Pereira
Lígia C. Gomes-da-Silva
Luis G. Arnaut
Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming
Scientific Reports
title Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming
title_full Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming
title_fullStr Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming
title_full_unstemmed Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming
title_short Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming
title_sort photodynamic therapy changes tumour immunogenicity and promotes immune checkpoint blockade response particularly when combined with micromechanical priming
url https://doi.org/10.1038/s41598-023-38862-8
work_keys_str_mv AT catarinaslobo photodynamictherapychangestumourimmunogenicityandpromotesimmunecheckpointblockaderesponseparticularlywhencombinedwithmicromechanicalpriming
AT mariainespmendes photodynamictherapychangestumourimmunogenicityandpromotesimmunecheckpointblockaderesponseparticularlywhencombinedwithmicromechanicalpriming
AT diogoapereira photodynamictherapychangestumourimmunogenicityandpromotesimmunecheckpointblockaderesponseparticularlywhencombinedwithmicromechanicalpriming
AT ligiacgomesdasilva photodynamictherapychangestumourimmunogenicityandpromotesimmunecheckpointblockaderesponseparticularlywhencombinedwithmicromechanicalpriming
AT luisgarnaut photodynamictherapychangestumourimmunogenicityandpromotesimmunecheckpointblockaderesponseparticularlywhencombinedwithmicromechanicalpriming